Treatment Options for Localized Prostate Cancer Based on Pretreatment Serum Prostate Specific Antigen Levels
- 1 August 1997
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 158 (2) , 319-325
- https://doi.org/10.1016/s0022-5347(01)64471-9
Abstract
No abstract availableThis publication has 63 references indexed in Scilit:
- Analysis of Risk Factors for Progression in Patients with Pathologically Confined Prostate Cancers After Radical Retropubic ProstatectomyJournal of Urology, 1996
- Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate CancerJournal of Urology, 1996
- Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam RadiationJournal of Urology, 1995
- A Multivariate Analysis of Clinical and Pathological Factors that Predict for Prostate Specific Antigen Failure after Radical Prostatectomy for Prostate CancerJournal of Urology, 1995
- Prostate Specific Antigen Density is not an Independent Predictor of Response for Prostate Cancer Treated by Conformal RadiotherapyJournal of Urology, 1995
- High failure rate associated with long‐term follow‐up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancerBritish Journal of Urology, 1995
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implicationsInternational Journal of Radiation Oncology*Biology*Physics, 1994
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Prostate-Specific Antigen: Its Role in Early Detection, Staging, and Monitoring of Prostatic CarcinomaJournal of Endourology, 1989